A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
The effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on systolic blood pressure (SBP) in patients with obesity with or without diabetes remains unclear. The aim was to compare the effect of different drug-dose combinations of GLP-1RAs o…
PURPOSE: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed, yet medication adherence varies. This study evaluated real-world adherence and persistence to semaglutide and e…
PURPOSE: This study aims to investigate the possible impacts of fasting on physical activity and weight loss in adult users of glucagon-like peptide-1 (GLP-1) agonists, specifically semaglutide and tirzepatide, using qualitative methods to gain in-de…
Obesity and diabetes are common among patients undergoing total hip arthroplasty (THA) and are associated with adverse outcomes. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were originally developed for glycaemic control but have recently b…
AIMS: Semaglutide has been shown to reduce cardiovascular events in non-diabetic patients with preexisting cardiovascular disease and overweight/obesity in the SELECT trial. Data on the applicability of these results to clinical practice are limited.…
AIMS: Weight loss mediated by glucagon-like peptide-1 (GLP-1) analogues is lower in patients with type 2 diabetes versus those without. Type 2 diabetes and obesity are risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD)…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) or glucagon receptor agonists have emerged as promising agents to treat metabolic dysfunction-associated steatotic liver…
BACKGROUND: Glucagon-like peptide-1 agonists like semaglutide are effective treatments for obesity. High costs may create economic barriers. This study examines the association between income and prescriptions for semaglutide for weight loss. METHODS…
GLP-1 receptor agonists (e.g., semaglutide) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) are effective for reducing body weight and fat mass, though lean soft tissue loss comprised 26%-40% of weight loss in recent trials. This case series…
BACKGROUND: Significant clinical efficacy has been shown for semaglutide in managing type 2 diabetes (T2D); however, its cost-effectiveness remains uncertain. PURPOSE: To systematically review existing evidence on cost-effectiveness of semaglutide ve…
The rising prevalence of youth-onset type 2 diabetes (T2D) in children necessitates early intervention with tight glycemic control, obesity medications, and metabolic and bariatric surgery (MBS). Insulin and metformin are standard treatments, but add…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populatio…
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase…
To address challenges such as limited loading capacity, restricted targeting precision, and low yield of natural exosomes as drug carriers, the fusion of liposomes and exosomes to create hybrid vesicles has emerged as a viable solution approach. Whil…
Obesity is associated with several comorbidities including Heart Failure with preserved Ejection Fraction (HFpEF), Metabolic dysfunction-Associated SteatoHepatitis (MASH), also termed MetALD when MASH patients have increased alcohol intake. The world…
PURPOSE: This review summarizes the comprehensive management of obesity with a focus on the pharmacology, efficacy, and safety of anti-obesity medications. SUMMARY: Obesity is a highly prevalent chronic disease with significant health risks, requirin…